Standards & Regulation

The Supreme Court will decide the fate of the abortion pill mifepristone in the US on March 26, 2024.

As incidents of DEG poisoning continue to occur, the IPEC Federation issues a call for companies not to be complacent when it comes to supply chains.

Three regulatory pathways for drug–device combinations – and why early action is key.

Introducing the British Standards Institution’s new environmental initiative to minimize antimicrobial resistance caused by manufacturing operations.

A drug development story: how one company filed a marketing authorization in Europe for a botanical drug to treat alopecia areata.

A look at the FDA’s safety investigation into CAR T therapeutics.

As the Sunshine State looks to import medicines to lower costs for Floridians, what of ongoing shortages for Canadians?

A video tour of the top FDA approvals from 2023

The details and reactions behind a recent FDA investigation into the cancer-risk of CAR-T therapies

How do we encourage the development of new cell and gene therapies without compromising our ethics?